If you have been watching Gilead Sciences lately, you know it's been a whirlwind, and not in a way that will leave you dizzy, ...
GV- and Arch-backed Pelage Pharma is developing a first-of-its-kind topical stem-cell therapy that could redefine the $10B ...
Gilead Sciences approaches Q3 2025 results on October 30, hitting new highs and presenting Livdelzi data at The Liver Meeting ...
Two studies demonstrate that a large proportion of the population has visceral adiposity even at BMIs below the obesity ...
Gilead Sciences will release its third-quarter earnings later this month, and analysts anticipate a single-digit bottom-line ...
(Yicai) Oct. 27 -- Gilead Sciences has benefited from China's accelerated regulatory reforms in granting market access for innovative drugs, with the country's pilot zones enabling near-simultaneous ...
Gilead (GILD) stock is in focus as the company halts a Phase 1 trial for its long-acting HIV injectable GS-1219, spotlighting ...
A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more? CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...
South Africa has become the first African country — and our medicines regulator the third worldwide — to register the revolutionary twice-a-year anti-HIV jab, lenacapavir (LEN). The shot could bring ...
Health Canada has granted conditional approval for Gilead Sciences’ Lyvdelzi for PBC patients who have difficulty with ...
After tense negotiations, Gilead Sciences has agreed not to boost prices next year for HIV medicines that are sold to state ...
CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback